Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Operating Margin: 2009-2025

Historic Operating Margin for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to 20.27%.

  • Amicus Therapeutics' Operating Margin rose 497.00% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.48%, marking a year-over-year increase of 442.00%. This contributed to the annual value of 4.71% for FY2024, which is 2404.00% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Operating Margin stood at 20.27%, which was up 430.96% from -6.12% recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Operating Margin peaked at 20.27% during Q3 2025, and registered a low of -95.71% during Q1 2022.
  • For the 3-year period, Amicus Therapeutics' Operating Margin averaged around -5.71%, with its median value being -6.12% (2025).
  • In the last 5 years, Amicus Therapeutics' Operating Margin plummeted by 2,492bps in 2022 and then skyrocketed by 5,512bps in 2023.
  • Amicus Therapeutics' Operating Margin (Quarterly) stood at -87.82% in 2021, then spiked by 3,977bps to -48.05% in 2022, then surged by 4,484bps to -3.21% in 2023, then surged by 1,388bps to 10.67% in 2024, then skyrocketed by 497bps to 20.27% in 2025.
  • Its Operating Margin was 20.27% in Q3 2025, compared to -6.12% in Q2 2025 and -6.35% in Q1 2025.